- Basilea Pharmaceutica AG press launch (OTC:BPMUF): FY GAAP EPS of CHF 5.83.
- Income of CHF 208.5M (+32.3% Y/Y).
- Working money stream considerably elevated to CHF 74M.
- Basilea exhibits a internet money place of CHF 28.6m as of December 31, 2024 (December 31, 2023: internet monetary debt of CHF 46.6m). Money and money equivalents and restricted money amounted to CHF 124.6m as of December 31, 2024 (December 31, 2023: CHF 64.3m).
-
Outlook:
(in CHFm) FY 2025e FY 2024 Cresemba and Zevtera-related income ~190 194.8 of which royalty earnings ~110 96.7 Whole income ~220 208.5 Analysis & improvement bills, internet ~88 77.1 Working revenue ~62 61.2
